This company listing is no longer active
Abcam (A8C1) Stock Overview
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A8C1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Abcam plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.70 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$12.20 |
| Beta | 0.78 |
| 1 Month Change | 0% |
| 3 Month Change | -8.67% |
| 1 Year Change | -14.85% |
| 3 Year Change | -18.26% |
| 5 Year Change | 0.74% |
| Change since IPO | 268.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| A8C1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 2.4% |
| 1Y | -14.9% | -5.0% | 5.0% |
Return vs Industry: A8C1 underperformed the German Biotechs industry which returned 7.6% over the past year.
Return vs Market: A8C1 underperformed the German Market which returned -13% over the past year.
Price Volatility
| A8C1 volatility | |
|---|---|
| A8C1 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: A8C1 has not had significant price volatility in the past 3 months.
Volatility Over Time: A8C1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 1,682 | Alan Hirzel | www.abcam.com |
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies.
Abcam plc Fundamentals Summary
| A8C1 fundamental statistics | |
|---|---|
| Market cap | €3.47b |
| Earnings (TTM) | €8.31m |
| Revenue (TTM) | €398.69m |
Is A8C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A8C1 income statement (TTM) | |
|---|---|
| Revenue | UK£350.40m |
| Cost of Revenue | UK£89.90m |
| Gross Profit | UK£260.50m |
| Other Expenses | UK£253.20m |
| Earnings | UK£7.30m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 74.34% |
| Net Profit Margin | 2.08% |
| Debt/Equity Ratio | 16.4% |
How did A8C1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/18 07:30 |
| End of Day Share Price | 2022/12/13 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abcam plc is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xian Deng | Berenberg |
| Michael Ryskin | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |